Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash & Equivalents (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash & Equivalents for 11 consecutive years, with $155.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 17.82% to $155.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $155.5 million through Dec 2025, down 17.82% year-over-year, with the annual reading at $155.5 million for FY2025, 17.82% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $155.5 million at Intellia Therapeutics, down from $193.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $523.5 million in Q4 2022, with the low at $120.5 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $189.1 million, with a median of $155.8 million recorded in 2025.
  • The sharpest move saw Cash & Equivalents plummeted 64.09% in 2021, then skyrocketed 317.18% in 2022.
  • Over 5 years, Cash & Equivalents stood at $125.5 million in 2021, then surged by 317.18% to $523.5 million in 2022, then tumbled by 56.69% to $226.7 million in 2023, then dropped by 16.57% to $189.2 million in 2024, then dropped by 17.82% to $155.5 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $155.5 million, $193.4 million, and $156.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.